Katie Kelley, MD, Hellen Diller Family Comprehensive Cancer Center

Articles by Katie Kelley, MD, Hellen Diller Family Comprehensive Cancer Center

Evolving HCC Treatment Landscape: Combination Therapy

ByPeter R. Galle, MD, PhD, Mainz University Medical Center,Pierre Gholam, MD, UH Westlake Health Center,Katie Kelley, MD, Hellen Diller Family Comprehensive Cancer Center,Richard S. Finn, MD, Geffen School of Medicine,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic

October 30th 2020

Developing Trial Regimens for Chinese Populations

ByPeter R. Galle, MD, PhD, Mainz University Medical Center,Pierre Gholam, MD, UH Westlake Health Center,Katie Kelley, MD, Hellen Diller Family Comprehensive Cancer Center,Richard S. Finn, MD, Geffen School of Medicine,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic

October 30th 2020

High AFP as Deciding Factor for Treatment

ByPeter R. Galle, MD, PhD, Mainz University Medical Center,Pierre Gholam, MD, UH Westlake Health Center,Katie Kelley, MD, Hellen Diller Family Comprehensive Cancer Center,Richard S. Finn, MD, Geffen School of Medicine,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic

October 30th 2020

Immunotherapy Monotherapy in Later-Line Setting

ByPeter R. Galle, MD, PhD, Mainz University Medical Center,Pierre Gholam, MD, UH Westlake Health Center,Katie Kelley, MD, Hellen Diller Family Comprehensive Cancer Center,Richard S. Finn, MD, Geffen School of Medicine,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic

October 30th 2020

Second-Line Options After IMbrave150 Regimen

ByPeter R. Galle, MD, PhD, Mainz University Medical Center,Pierre Gholam, MD, UH Westlake Health Center,Katie Kelley, MD, Hellen Diller Family Comprehensive Cancer Center,Richard S. Finn, MD, Geffen School of Medicine,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic

October 30th 2020

Promising Ongoing Frontline Trials

ByPeter R. Galle, MD, PhD, Mainz University Medical Center,Pierre Gholam, MD, UH Westlake Health Center,Katie Kelley, MD, Hellen Diller Family Comprehensive Cancer Center,Richard S. Finn, MD, Geffen School of Medicine,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic

October 30th 2020

Importance of Endoscopy in Newly Diagnosed HCC

ByPeter R. Galle, MD, PhD, Mainz University Medical Center,Pierre Gholam, MD, UH Westlake Health Center,Katie Kelley, MD, Hellen Diller Family Comprehensive Cancer Center,Richard S. Finn, MD, Geffen School of Medicine,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic

October 30th 2020

NCCN Guidelines: Nivolumab in Frontline Setting

ByPeter R. Galle, MD, PhD, Mainz University Medical Center,Pierre Gholam, MD, UH Westlake Health Center,Katie Kelley, MD, Hellen Diller Family Comprehensive Cancer Center,Richard S. Finn, MD, Geffen School of Medicine,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic

October 30th 2020

Choosing a Frontline Therapy

ByPeter R. Galle, MD, PhD, Mainz University Medical Center,Pierre Gholam, MD, UH Westlake Health Center,Katie Kelley, MD, Hellen Diller Family Comprehensive Cancer Center,Richard S. Finn, MD, Geffen School of Medicine,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic

October 30th 2020

Optimal HCC Frontline Treatments

ByPeter R. Galle, MD, PhD, Mainz University Medical Center,Pierre Gholam, MD, UH Westlake Health Center,Katie Kelley, MD, Hellen Diller Family Comprehensive Cancer Center,Richard S. Finn, MD, Geffen School of Medicine,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic

October 30th 2020

The TACE Approach for Intermediate-Stage Disease

ByPeter R. Galle, MD, PhD, Mainz University Medical Center,Pierre Gholam, MD, UH Westlake Health Center,Katie Kelley, MD, Hellen Diller Family Comprehensive Cancer Center,Richard S. Finn, MD, Geffen School of Medicine,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic

October 30th 2020

The BCLC Staging System

ByPeter R. Galle, MD, PhD, Mainz University Medical Center,Pierre Gholam, MD, UH Westlake Health Center,Katie Kelley, MD, Hellen Diller Family Comprehensive Cancer Center,Richard S. Finn, MD, Geffen School of Medicine,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic

October 30th 2020

Screening Vs Diagnosis: Assessing Liver Function

ByPeter R. Galle, MD, PhD, Mainz University Medical Center,Pierre Gholam, MD, UH Westlake Health Center,Katie Kelley, MD, Hellen Diller Family Comprehensive Cancer Center,Richard S. Finn, MD, Geffen School of Medicine,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic

October 30th 2020

The Complexity of HCC Multidisciplinary Management

ByPeter R. Galle, MD, PhD, Mainz University Medical Center,Pierre Gholam, MD, UH Westlake Health Center,Katie Kelley, MD, Hellen Diller Family Comprehensive Cancer Center,Richard S. Finn, MD, Geffen School of Medicine,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic

October 30th 2020

Hepatocellular Carcinoma: A Rapidly Evolving Treatment Landscape

ByPeter R. Galle, MD, PhD, Mainz University Medical Center,Pierre Gholam, MD, UH Westlake Health Center,Katie Kelley, MD, Hellen Diller Family Comprehensive Cancer Center,Richard S. Finn, MD, Geffen School of Medicine,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic

October 30th 2020

Discussion around topics pertaining to the use of systemic therapy in advanced liver cancer. Topics will include the latest research in the field and the impact of recent clinical trials on making decisions around treatment selection.

Latest Updated Articles

Screening Vs Diagnosis: Assessing Liver Function
Published: October 30th 2020 | Updated:
Immunotherapy Monotherapy in Later-Line Setting
Published: October 30th 2020 | Updated:
NCCN Guidelines: Nivolumab in Frontline Setting
Published: October 30th 2020 | Updated:
The TACE Approach for Intermediate-Stage Disease
Published: October 30th 2020 | Updated:
Choosing a Frontline Therapy
Published: October 30th 2020 | Updated:
Second-Line Options After IMbrave150 Regimen
Published: October 30th 2020 | Updated:

Katie Kelley, MD, Hellen Diller Family Comprehensive Cancer Center

Articles by Katie Kelley, MD, Hellen Diller Family Comprehensive Cancer Center

Evolving HCC Treatment Landscape: Combination Therapy

Developing Trial Regimens for Chinese Populations

High AFP as Deciding Factor for Treatment

Immunotherapy Monotherapy in Later-Line Setting

Second-Line Options After IMbrave150 Regimen

Promising Ongoing Frontline Trials

Importance of Endoscopy in Newly Diagnosed HCC

NCCN Guidelines: Nivolumab in Frontline Setting

Choosing a Frontline Therapy

Optimal HCC Frontline Treatments

The TACE Approach for Intermediate-Stage Disease

The BCLC Staging System

Screening Vs Diagnosis: Assessing Liver Function

The Complexity of HCC Multidisciplinary Management

Hepatocellular Carcinoma: A Rapidly Evolving Treatment Landscape

Latest Updated Articles

Trending on OncLive

FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma

PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer

NP-G1-044 Receives FDA Orphan Drug Designation for Pancreatic Cancer

Meta-Analysis Characterizes Nivolumab/Ipilimumab Hyperprogression in Renal Medullary Carcinoma

Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma